# BARDA DRIVe EZ-BAA (EZBAA - 22-100-SOL-00003)

Canonical: https://abierto.us/opportunities/75a50126c00005

- Solicitation number: 75A50126C00005
- Notice type: Award notice
- Status: Awarded to Isola Therapeutics Inc. for $7,485,416.99
- Department: Department of Health and Human Services
- Agency: Office of Assistant Secretary for Preparedness and Response
- Contracting office: Barda - Aspr / Daappo / Barda DCMA (75A501)
- NAICS: 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Product or service code: AN13 Health R&D Services; Health Care Services; Experimental Development
- Place of performance: Minneapolis, Minnesota
- County: Hennepin County (FIPS 27053). https://abierto.us/counties/hennepin-county-mn-27053
- City: Minneapolis. https://abierto.us/cities/minneapolis-mn-2743000
- First posted: April 27, 2026
- Last posted: April 27, 2026
- SAM.gov: https://sam.gov/workspace/contract/opp/39c9f7980c97409ca9cdf6d422b5cdda/view

## Description

The purpose of the proposed Contract is for Nebulization Therapy to Prevent and Treat Pulmonary Foam Caused by Inhaled Chemical Agents. The primary goal of the R&D effort described in this statement of work (SOW) is to generate the necessary data and information to support an initial FDA meeting to align on the regulatory strategy.

The contract scope includes early-stage formulation and analytical development of the drug product; nebulizer characterization including flow rates and particle size distribution; bioanalytical development to support non-GLP studies using the proposed test article including PK, dose range finding, and chlorine exposure proof-of-concept (POC); and development of an overall regulatory strategy.

This scope of work is expected to support a productive FDA engagement and advance the technical readiness level (TRL) through TRL 5 to meet minimum requirements to support various future contract vehicles. The generated data and completed non-GLP studies, along with FDA feedback, will inform work required in later development phases.

## Award on USAspending

- Recipient: Isola Therapeutics Inc. (UEI M3QDM72NME75)
- Contract: 75A50126C00005, definitive contract
- Obligated: $7,485,416.99
- Competition: Full and Open Competition, 1 offers received
- Link: award number 75A50126C00005 equals the contract number; same awarding office 75A501 (high confidence)
- Record: https://www.usaspending.gov/award/CONT_AWD_75A50126C00005_7505_-NONE-_-NONE-/


## Publications

- April 27, 2026: Award notice. Notice 39c9f7980c97409ca9cdf6d422b5cdda. https://sam.gov/workspace/contract/opp/39c9f7980c97409ca9cdf6d422b5cdda/view

## Points of contact

- BARDA DCMA DRIVe Team, DRIVeAcquisitions@hhs.gov
- Richard Hall, Richard.Hall@hhs.gov

---
Source: SAM.gov Contract Opportunities bulk extract and USAspending.gov award data. Confirm deadlines on SAM.gov before responding. Cite https://abierto.us/opportunities/75a50126c00005.